The Draft Pharmaceutical Policy 2017 has been introduced by the Department of Pharmaceuticals with the objective of regulating the production and marketing of pharmaceutical products in India. Salient Features Key features of this policy are as follows: Price Control to Monitoring The new policy has an aim of reorienting the Drug Price Control Order (DPCO)
People in India frequently suffer from joint pain and arthritis. There has been a rise in the cases of surgeries and knee replacements by 30% from 2004 to 2008. The huge profit margin extracted out of the business of knee implants has made the National Pharmaceutical Pricing Authority (NPPA) to slash prices of such implants.
The National Pharmaceutical Pricing Authority (NPPA) is a regulatory agency functioning under the aegis of Union Ministry of Chemical and Fertiliser. NPPA is not a statutory body and was formed in 1997 to fix/revise the prices of controlled bulk drugs and formulations as well as to enforce prices and availability of medicines under the Drugs